The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced today that the U.S. Food and Drug Administration (FDA) designated Otulfi® (ustekinumab-aauz) as an interchangeable ...

The primary endpoint was met, with 57% of subjects treated with the therapy achieving clear or almost clear skin.

In a smaller subset of subjects having hand/foot psoriasis ... to shift the treatment paradigm in moderate-to-severe plaque psoriasis, by offering a combination of skin clearance and favourable ...

and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint. Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in ...

Get more information about phototherapy from the sun or a light box and how it may be a safe, effective treatment for your plaque ... for psoriasis that hasn’t responded to other treatments or the ...

Accessed April 2025. 6 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles ...

A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL).

and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.6 About Plaque PsoriasisPlaque psoriasis (PsO) is a chronic immune-mediated ...